Mount Sinai launches clinical trial to treat chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

Mount Sinai has the largest Sarcoidosis Service in the world and is one of only two institutions in the country participating in the trial; the other is the University of Cincinnati. Mount Sinai is a National Institutes of Health for research in sarcoidosis.

"The current standard treatment for chronic pulmonary sarcoidosis is ," said Adam Morgenthau, MD, principal investigator of the study and Director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at Mount Sinai. "Many patients don't respond to these drugs and those who do often develop long-term complications. We are hopeful this study will lead to new treatments to improve and quality of life."

Sarcoidosis is a rare inflammatory disease that can affect any organ but most commonly involves the lungs. Patients with pulmonary sarcoidosis typically exhibit symptoms of shortness of breath, cough and/or wheeze. It affects men and women of all ages and races worldwide. However, it occurs mostly in people ages 20 to 40, African Americans, especially women, and people of Asian, German, Irish, Puerto Rican and Scandinavian origin, according to the National Institutes of Health.

The randomized placebo Phase II clinical trial at Mount Sinai for patients with sarcoidosis is designed to assess the safety, tolerability and efficacy of an antibody directed against macrophage colony-stimulating factor (m-CSF), a protein associated with the development of sarcoidosis. During a Phase I clinical trial for patients with (RA), the antibody was well tolerated in healthy people as well as patients with RA.

"This study has both clinical and basic science applications," said Dr. Morgenthau. "In addition to determining whether patients' symptoms improve with this treatment, we will examine cell signaling pathways and immune responses in the trial participants which will help us better understand the biology of sarcoidosis and ultimately lead to the development of therapies that target the immune response."

add to favorites email to friend print save as pdf

Related Stories

Biosignatures distinguish between tuberculosis and sarcoidosis

May 07, 2012

With a range of diseases, doctors need unique features which they can use to unequivocally identify a patient's illness for an appropriate diagnosis. Scientists therefore search for the biomarkers for an illness or a combination ...

Recommended for you

Obama addresses West Africans on facts about Ebola

2 hours ago

President Barack Obama urged West Africans on Tuesday to wear gloves and masks when caring for Ebola patients or burying anyone who died of the disease. He also discouraged the traditional burial practice ...

Gluten-free diet benefits asymptomatic EmA+ adults

2 hours ago

(HealthDay)—Asymptomatic individuals with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD), according to a study published in the September issue of Gastroenterology.

Another US health worker infected with Ebola

3 hours ago

A third American health worker has tested positive for the Ebola virus while working with patients in West Africa, the Christian missionary group SIM said Tuesday.

UN implores all countries to help on Ebola

5 hours ago

The international group Doctor Without Borders warned Tuesday that the world is 'losing the battle' against Ebola, while U.N. officials implored all countries to quickly step up their response by contributing health experts ...

Travel restrictions could worsen Ebola crisis: experts

9 hours ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

User comments